Interferon‐gamma–mediated tissue factor expression contributes to T‐cell‐mediated hepatitis through induction of hypercoagulation in mice

Junko Kato, Tomohiro Okamoto, Hiroyuki Motoyama, Ryosuke Uchiyama, Daniel Kirchhofer, Nico Van Rooijen, Hirayuki Enomoto, Shuhei Nishiguchi, Norifumi Kawada, Jiro Fujimoto, Hiroko Tsutsui – 30 August 2012 – Concanavalin A (Con A) treatment induces severe hepatitis in mice in a manner dependent on T cells, interferon (IFN)‐gamma, and tumor necrosis factor (TNF). Treatment with the anticoagulant heparin protects against hepatitis, despite healthy production of IFN‐γ and TNF. Here, we investigated molecular and cellular mechanisms for hypercoagulation‐mediated hepatitis.

Validation of terminal peptide of procollagen III for the detection and assessment of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease

Sudeep Tanwar, Paul M. Trembling, Indra N. Guha, Julie Parkes, Philip Kaye, Alastair D. Burt, Stephen D. Ryder, Guruprasad P. Aithal, Christopher P. Day, William M. Rosenberg – 29 August 2012 – Liver biopsy is the reference standard for the detection of nonalcoholic steatohepatitis (NASH) within nonalcoholic fatty liver disease (NAFLD). The aim of this study was to identify a biomarker of NASH in patients without significant fibrosis. In all, 172 patients from two centers with biopsy‐proven NAFLD were included in this study.

Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms

Alessia Bortoluzzi, Giulio Ceolotto, Elisabetta Gola, Antonietta Sticca, Sergio Bova, Filippo Morando, Salvatore Piano, Silvano Fasolato, Silvia Rosi, Angelo Gatta, Paolo Angeli – 22 August 2012 – The aim of this study was to evaluate the effect and molecular mechanism of albumin infusion on cardiac contractility in experimental cirrhosis with ascites. Cardiac contractility was recorded ex vivo in rats with cirrhosis and ascites and in control rats after the injection in the caudal vein of albumin, saline, or hydroxyethyl starch (HES).

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid

Akira Honda, Tadashi Ikegami, Makoto Nakamuta, Teruo Miyazaki, Junichi Iwamoto, Takeshi Hirayama, Yoshifumi Saito, Hajime Takikawa, Michio Imawari, Yasushi Matsuzaki – 22 August 2012 – Bezafibrate is a widely used hypolipidemic agent and is known as a ligand of the peroxisome proliferator‐activated receptors (PPARs). Recently this agent has come to be recognized as a potential anticholestatic medicine for the treatment of primary biliary cirrhosis (PBC) that does not respond sufficiently to ursodeoxycholic acid (UDCA) monotherapy.

Subscribe to